相关实验视频

Updated: Apr 7, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

与化相关的基因特征预测NSCLC的预后和抗辐射性

Jianmin Liu¹, Juan Wang², Jia Wang³

¹Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, China; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

Translational oncology

|August 21, 2025

概括

这项研究确定了与非小细胞肺癌 (NSCLC) 相关的关键基因,开发了一个预后模型来预测患者的结果,并指导个性化放射治疗策略以提高治疗效果.

科学领域:

癌症学
分子生物学
基因组学

背景情况:

非小细胞肺癌 (NSCLC) 的死亡率很高,治疗选择有限.
由营养缺乏和输送蛋白过度表达引发的受调的细胞死亡途径 - - 失硫症影响NSCLC患者的预后.
对于开发新型NSCLC治疗策略来说,了解二硫症机制至关重要.

研究的目的:

在NSCLC中识别与二硫症相关的基因 (DAPG).
构建和验证基于DAPG的NSCLC患者的预后模型.
在NSCLC中研究二硫和放射治疗反应之间的关联.

主要方法:

对TCGA和GEO数据集进行共识集群,以确定DAPG.
使用生存分析开发和验证预后模型.
对基因组突变,免疫透和放射治疗反应的分析.
在耐辐射NSCLC细胞系中探索与化相关的基因表达.

主要成果:

确定了9个DAPG,形成了一个预后模型 (DRRS).
在高和低DRRS组之间观察到不同的预后,基因组和免疫透概况.
该预后模型准确地预测了放射治疗患者的结果,KIF14与DNA修复和放射电阻有很强的联系.

结论:

一个与硫化相关的预后模型可以区分NSCLC患者的结果,从而实现个性化治疗.
已识别的DAPG,特别是KIF14,为克服放射性耐药性提供了潜在的目标.
这项研究有助于更好地理解二硫化与NSCLC疗法的相互作用.

关键词:

脱硫化免疫透在 NSCLC 预测模型无线电阻瘤微环境

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...